MR imaging of multiple sclerosis

Radiology

Volumn 259, Issue 3, 2011, Pages 659-681

  Filippi, Massimo ^a   Rocca, Maria A ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; GADOLINIUM; ULTRASMALL SUPERPARAMAGNETIC IRON OXIDE;

BRAIN ATROPHY; BRAIN SIZE; CELL INFILTRATION; CONTRAST ENHANCEMENT; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DIFFUSION TENSOR IMAGING; DISEASE ACTIVITY; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HUMAN; IMAGE PROCESSING; IRON STORAGE; MACROPHAGE FUNCTION; MAGNETIC FIELD; MULTIPLE SCLEROSIS; NEUROIMAGING; NEUROPATHOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OPTIC NERVE; PATIENT MONITORING; PERFUSION WEIGHTED IMAGING; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SIGNAL NOISE RATIO; SPINAL CORD; SYNDROME DELINEATION; TREATMENT RESPONSE; VOXEL BASED MORPHOMETRY;

CONTRAST MEDIA; DISEASE PROGRESSION; HUMANS; MAGNETIC RESONANCE IMAGING; MULTIPLE SCLEROSIS;

EID: 79956324393     PISSN: 00338419     EISSN: 15271315     Source Type: Journal    
DOI: 10.1148/radiol.11101362     Document Type: Review

References (203)

1. Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG. Multiple sclerosis. N Engl J Med 2000;343(13):938-952.
2. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 1996;46(4):907-911. (Pubitemid 26134623)
3. Hawkins SA, McDonnell GV. Benign multiple sclerosis? clinical course, long term follow up, and assessment of prognostic factors. J Neurol Neurosurg Psychiatry 1999;67(2):148-152. (Pubitemid 29326942)
4. Miller DH, Leary SM. Primary-progressive multiple sclerosis. Lancet Neurol 2007;6(10):903-912. (Pubitemid 47405002)
5. Brex PA, Ciccarelli O, O'Riordan JI, Sailer M, Thompson AJ, Miller DH. A longitudinal study of abnormalities on MRI and disability from multiple sclerosis. N Engl J Med 2002;346(3):158-164. (Pubitemid 34438881)
6. Fisniku LK, Brex PA, Altmann DR, et al. Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis. Brain 2008;131(Pt 3):808-817. (Pubitemid 351294716)
7. McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the international panel on the diagnosis of multiple sclerosis. Ann Neurol 2001;50(1):121-127.
8. Charil A, Yousry TA, Rovaris M, et al. MRI and the diagnosis of multiple sclerosis: expanding the concept of "no better explanation". Lancet Neurol 2006;5(10):841-852.
9. Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald criteria". Ann Neurol 2005;58(6):840-846.
10. Swanton JK, Fernando K, Dalton CM, et al. Modification of MRI criteria for multiple sclerosis in patients with clinically isolated syndromes. J Neurol Neurosurg Psychiatry 2006;77(7):830-833. (Pubitemid 44023177)
11. Swanton JK, Rovira A, Tintore M, et al. MRI criteria for multiple sclerosis in patients presenting with clinically isolated syndromes: a multicentre retrospective study. Lancet Neurol 2007;6(8):677-686. (Pubitemid 47064439)
12. Rovira A, Swanton J, Tintoré M, et al. A single, early magnetic resonance imaging study in the diagnosis of multiple sclerosis. Arch Neurol 2009;66(5):587-592.
13. Montalban X, Tintoré M, Swanton J, et al. MRI criteria for MS in patients with clinically isolated syndromes. Neurology 2010;74(5):427-434.
14. Okuda DT, Mowry EM, Beheshtian A, et al. Incidental MRI anomalies suggestive of multiple sclerosis: the radiologically isolated syndrome. Neurology 2009;72(9):800-805.
15. Lebrun C, Bensa C, Debouverie M, et al. Association between clinical conversion to multiple sclerosis in radiologically isolated syndrome and magnetic resonance imaging, cerebrospinal fluid, and visual evoked potential: follow-up of 70 patients. Arch Neurol 2009;66(7):841-846.
16. Siva A, Saip S, Altintas A, Jacob A, Keegan BM, Kantarci OH. Multiple sclerosis risk in radiologically uncovered asymptomatic possible inflammatory-demyelinating disease . Mult Scler 2009;15(8):918-927.
17. Paty DW, Li DK, Oger JJ, et al. Magnetic resonance imaging in the evaluation of clinical trials in multiple sclerosis. Ann Neurol 1994;36(Suppl):S95-S96. (Pubitemid 24220850)
18. Thompson AJ, Miller DH, MacManus DG, McDonald WI. Patterns of disease activity in multiple sclerosis. BMJ 1990;301(6742):44-45. (Pubitemid 20211008)
19. Filippi M, Rocca MA. Conventional MRI in multiple sclerosis. J Neuroimaging 2007;17(Suppl 1):3S-9S.
20. Bakshi R, Thompson AJ, Rocca MA, et al. MRI in multiple sclerosis: current status and future prospects. Lancet Neurol 2008;7(7):615-625.
21. Sormani MP, Rovaris M, Comi G, Filippi M. A reassessment of the plateauing relationship between T2 lesion load and disability in MS. Neurology 2009;73(19):1538-1542.
22. Li DK, Held U, Petkau J, et al. MRI T2 lesion burden in multiple sclerosis: a plateauing relationship with clinical disability. Neurology 2006;66(9):1384-1389. (Pubitemid 43739648)
23. Kermode AG, Thompson AJ, Tofts P, et al. Breakdown of the blood-brain barrier precedes symptoms and other MRI signs of new lesions in multiple sclerosis. Pathogenetic and clinical implications. Brain 1990;113(Pt 5):1477-1489. (Pubitemid 20385925)
24. Thompson AJ, Miller D, Youl B, et al. Serial gadolinium-enhanced MRI in relapsing/remitting multiple sclerosis of varying disease duration. Neurology 1992;42(1):60-63.
25. Thompson AJ, Kermode AG, Wicks D, et al. Major differences in the dynamics of primary and secondary progressive multiple sclerosis. Ann Neurol 1991;29(1):53-62.
26. Filippi M, Rossi P, Campi A, Colombo B, Pereira C, Comi G. Serial contrast-enhanced MR in patients with multiple sclerosis and varying levels of disability. AJNR Am J Neuroradiol 1997;18(8):1549-1556. (Pubitemid 30413972)
27. Zhao Y, Petkau AJ, Traboulsee A, Riddehough A, Li DK. Does MRI lesion activity regress in secondary progressive multiple sclerosis? Mult Scler 2010;16(4):434-442.
28. Kappos L, Moeri D, Radue EW, et al. Predictive value of gadolinium-enhanced magnetic resonance imaging for relapse rate and changes in disability or impairment in multiple sclerosis: a meta-analysis. Gadolinium MRI Meta-analysis Group. Lancet 1999;353(9157):964-969. (Pubitemid 29132605)
29. Simon JH, Li D, Traboulsee A, et al. Standardized MR imaging protocol for multiple sclerosis: Consortium of MS Centers consensus guidelines. AJNR Am J Neuroradiol 2006;27(2):455-461. (Pubitemid 44897861)
30. Lövblad KO, Anzalone N, Dörfler A, et al. MR imaging in multiple sclerosis: review and recommendations for current practice. AJNR Am J Neuroradiol 2010;31(6):983-989.
31. Vellinga MM, Oude Engberink RD, Seewann A, et al. Pluriformity of inflammation in multiple sclerosis shown by ultra-small iron oxide particle enhancement. Brain 2008;131(Pt 3):800-807. (Pubitemid 351294725)
32. Dawson KT. The histology of multiple sclerosis. Trans R Soc Edinb 1916;50:517-740.
33. Geurts JJ, Pouwels PJ, Uitdehaag BM, Polman CH, Barkhof F, Castelijns JA. Intracortical lesions in multiple sclerosis: improved detection with 3D double inversion-recovery MR imaging. Radiology 2005;236(1):254-260. (Pubitemid 40853320)
34. Calabrese M, De Stefano N, Atzori M, et al. Detection of cortical inflammatory lesions by double inversion recovery magnetic resonance imaging in patients with multiple sclerosis. Arch Neurol 2007;64(10):1416-1422. (Pubitemid 47572665)
35. Calabrese M, Filippi M, Rovaris M, et al. Evidence for relative cortical sparing in benign multiple sclerosis: a longitudinal magnetic resonance imaging study. Mult Scler 2009;15(1):36-41.
36. Calabrese M, Rocca MA, Atzori M, et al. Cortical lesions in primary progressive multiple sclerosis: a 2-year longitudinal MR study. Neurology 2009;72(15):1330-1336.
37. Roosendaal SD, Moraal B, Vrenken H, et al. In vivo MR imaging of hippocampal lesions in multiple sclerosis. J Magn Reson Imaging 2008;27(4):726-731.
38. Calabrese M, Rocca MA, Atzori M, et al. A 3-year magnetic resonance imaging study of cortical lesions in relapse-onset multiple sclerosis. Ann Neurol 2010;67(3):376-383.
39. Calabrese M, Filippi M, Rovaris M, et al. Morphology and evolution of cortical lesions in multiple sclerosis. A longitudinal MRI study. Neuroimage 2008;42(4):1324-1328.
40. Roosendaal SD, Moraal B, Pouwels PJ, et al. Accumulation of cortical lesions in MS: relation with cognitive impairment. Mult Scler 2009;15(6):708-714.
41. Calabrese M, Agosta F, Rinaldi F, et al. Cortical lesions and atrophy associated with cognitive impairment in relapsing-remitting multiple sclerosis. Arch Neurol 2009;66(9):1144-1150.
42. Kidd D, Barkhof F, McConnell R, Algra PR, Allen IV, Revesz T. Cortical lesions in multiple sclerosis. Brain 1999;122(Pt 1):17-26. (Pubitemid 29046269)
43. Pouwels PJ, Kuijer JP, Mugler JP 3rd, Guttmann CR, Barkhof F. Human gray matter: feasibility of single-slab 3D double inversion-recovery high-spatial-resolution MR imaging. Radiology 2006;241(3):873-879. (Pubitemid 46190555)
44. Nelson F, Poonawalla AH, Hou P, Huang F, Wolinsky JS, Narayana PA. Improved identification of intracortical lesions in multiple sclerosis with phase-sensitive inversion recovery in combination with fast double inversion recovery MR imaging. AJNR Am J Neuroradiol 2007;28(9):1645-1649. (Pubitemid 47598132)
45. Nelson F, Poonawalla A, Hou P, Wolinsky JS, Narayana PA. 3D MPRAGE improves classification of cortical lesions in multiple sclerosis. Mult Scler 2008;14(9):1214-1219.
46. Miller DH, Barkhof F, Frank JA, Parker GJ, Thompson AJ. Measurement of atrophy in multiple sclerosis: pathological basis, methodological aspects and clinical relevance. Brain 2002;125(Pt 8):1676-1695.
47. Bermel RA, Bakshi R. The measurement and clinical relevance of brain atrophy in multiple sclerosis. Lancet Neurol 2006;5(2):158-170. (Pubitemid 43107851)
48. Giorgio A, Battaglini M, Smith SM, De Stefano N. Brain atrophy assessment in multiple sclerosis: importance and limitations. Neuroimaging Clin N Am 2008;18(4):675-686, xi.
49. Lanz M, Hahn HK, Hildebrandt H. Brain atrophy and cognitive impairment in multiple sclerosis: a review. J Neurol 2007;254(Suppl 2):II43-II48.
50. Fisher E, Rudick RA, Simon JH, et al. Eight-year follow-up study of brain atrophy in patients with MS. Neurology 2002;59(9):1412-1420. (Pubitemid 35285996)
51. Khaleeli Z, Ciccarelli O, Manfredonia F, et al. Predicting progression in primary progressive multiple sclerosis: a 10-year multicenter study. Ann Neurol 2008;63(6):790-793. (Pubitemid 351945538)
52. De Stefano N, Giorgio A, Battaglini M, et al. Assessing brain atrophy rates in a large population of untreated multiple sclerosis subtypes. Neurology 2010;74(23):1868-1876.
53. Chard DT, Griffin CM, Parker GJ, Kapoor R, Thompson AJ, Miller DH. Brain atrophy in clinically early relapsing-remitting multiple sclerosis. Brain 2002;125(Pt 2):327-337. (Pubitemid 34127435)
54. De Stefano N, Matthews PM, Filippi M, et al. Evidence of early cortical atrophy in MS: relevance to white matter changes and disability. Neurology 2003;60(7):1157-1162. (Pubitemid 36418778)
55. Tedeschi G, Lavorgna L, Russo P, et al. Brain atrophy and lesion load in a large population of patients with multiple sclerosis. Neurology 2005;65(2):280-285. (Pubitemid 41022375)
56. Sanfilipo MP, Benedict RH, Sharma J, Weinstock-Guttman B, Bakshi R. The relationship between whole brain volume and disability in multiple sclerosis: a comparison of normalized gray vs. white matter with misclassification correction. Neuroimage 2005;26(4):1068-1077. (Pubitemid 40806485)
57. Prinster A, Quarantelli M, Lanzillo R, et al. A voxel-based morphometry study of disease severity correlates in relapsing- remitting multiple sclerosis. Mult Scler 2010;16(1):45-54.
58. Amato MP, Portaccio E, Goretti B, et al. Association of neocortical volume changes with cognitive deterioration in relapsing-remitting multiple sclerosis. Arch Neurol 2007;64(8):1157-1161. (Pubitemid 47258075)
59. Benedict RH, Bruce JM, Dwyer MG, et al. Neocortical atrophy, third ventricular width, and cognitive dysfunction in multiple sclerosis. Arch Neurol 2006;63(9):1301-1306. (Pubitemid 44379833)
60. Valsasina P, Benedetti B, Rovaris M, Sormani MP, Comi G, Filippi M. Evidence for progressive gray matter loss in patients with relapsing-remitting MS. Neurology 2005;65(7):1126-1128. (Pubitemid 41429650)
61. Chen JT, Narayanan S, Collins DL, Smith SM, Matthews PM, Arnold DL. Relating neocortical pathology to disability progression in multiple sclerosis using MRI. Neuroimage 2004;23(3):1168-1175. (Pubitemid 39446548)
62. Fisher E, Lee JC, Nakamura K, Rudick RA. Gray matter atrophy in multiple sclerosis: a longitudinal study. Ann Neurol 2008;64(3):255-265.
63. Henry RG, Shieh M, Okuda DT, Evangelista A, Gorno-Tempini ML, Pelletier D. Regional grey matter atrophy in clinically isolated syndromes at presentation. J Neurol Neurosurg Psychiatry 2008;79(11):1236-1244.
64. Bendfeldt K, Kappos L, Radue EW, Borgwardt SJ. Progression of gray matter atrophy and its association with white matter lesions in relapsing-remitting multiple sclerosis. J Neurol Sci 2009;285(1-2):268-269; author reply 269.
65. Ceccarelli A, Rocca MA, Pagani E, et al. A voxel-based morphometry study of grey matter loss in MS patients with different clinical phenotypes. Neuroimage 2008;42(1):315-322.
66. Mesaros S, Rovaris M, Pagani E, et al. A magnetic resonance imaging voxel-based morphometry study of regional gray matter atrophy in patients with benign multiple sclerosis. Arch Neurol 2008;65(9):1223-1230.
67. Mesaros S, Rocca MA, Absinta M, et al. Evidence of thalamic gray matter loss in pediatric multiple sclerosis. Neurology 2008;70(13 Pt 2):1107-1112. (Pubitemid 351464767)
68. Riccitelli G, Rocca MA, Pagani E, et al. Cognitive impairment in multiple sclerosis is associated to different patterns of gray matter atrophy according to clinical phenotype. Hum Brain Mapp 2010 Aug 25. [Epub ahead of print]
69. Sicotte NL, Kern KC, Giesser BS, et al. Regional hippocampal atrophy in multiple sclerosis. Brain 2008;131(Pt 4):1134-1141. (Pubitemid 351499428)
70. Sepulcre J, Masdeu JC, Goñi J, et al. Fatigue in multiple sclerosis is associated with the disruption of frontal and parietal pathways. Mult Scler 2009;15(3):337-344.
71. Pellicano C, Gallo A, Li X, et al. Relationship of cortical atrophy to fatigue in patients with multiple sclerosis. Arch Neurol 2010;67(4):447-453.
72. Bendfeldt K, Blumhagen JO, Egger H, et al. Spatiotemporal distribution pattern of white matter lesion volumes and their association with regional grey matter volume reductions in relapsing-remitting multiple sclerosis. Hum Brain Mapp 2010;31(10):1542-1555.
73. Bendfeldt K, Kuster P, Traud S, et al. Association of regional gray matter volume loss and progression of white matter lesions in multiple sclerosis-A longitudinal voxel-based morphometry study. Neuroimage 2009;45(1):60-67.
74. Filippi M, Agosta F. Magnetization transfer MRI in multiple sclerosis. J Neuroimaging 2007;17(Suppl 1):22S-26S.
75. van Waesberghe JH, Kamphorst W, De Groot CJ, et al. Axonal loss in multiple sclerosis lesions: magnetic resonance imaging insights into substrates of disability. Ann Neurol 1999;46(5):747-754. (Pubitemid 29518136)
76. Schmierer K, Scaravilli F, Altmann DR, Barker GJ, Miller DH. Magnetization transfer ratio and myelin in postmortem multiple sclerosis brain. Ann Neurol 2004;56(3):407-415. (Pubitemid 39166560)
77. Amato MP, Portaccio E, Stromillo ML, et al. Cognitive assessment and quantitative magnetic resonance metrics can help to identify benign multiple sclerosis. Neurology 2008;71(9):632-638.
78. Agosta F, Rovaris M, Pagani E, Sormani MP, Comi G, Filippi M. Magnetization transfer MRI metrics predict the accumulation of disability 8 years later in patients with multiple sclerosis. Brain 2006;129(Pt 10):2620-2627. (Pubitemid 44522095)
79. Khaleeli Z, Altmann DR, Cercignani M, Ciccarelli O, Miller DH, Thompson AJ. Magnetization transfer ratio in gray matter: a potential surrogate marker for progression in early primary progressive multiple sclerosis. Arch Neurol 2008;65(11):1454-1459.
80. Penny S, Khaleeli Z, Cipolotti L, Thompson A, Ron M. Early imaging predicts later cognitive impairment in primary progressive multiple sclerosis. Neurology 2010;74(7):545-552.
81. Chen JT, Collins DL, Atkins HL, Freedman MS, Arnold DL; Canadian MS/BMT Study Group. Magnetization transfer ratio evolution with demyelination and remyelination in multiple sclerosis lesions. Ann Neurol 2008;63(2):254-262.
82. Khaleeli Z, Cercignani M, Audoin B, Ciccarelli O, Miller DH, Thompson AJ. Localized grey matter damage in early primary progressive multiple sclerosis contributes to disability. Neuroimage 2007;37(1):253-261. (Pubitemid 47068988)
83. Ranjeva JP, Audoin B, Au Duong MV, et al. Local tissue damage assessed with statistical mapping analysis of brain magnetization transfer ratio: relationship with functional status of patients in the earliest stage of multiple sclerosis. AJNR Am J Neuroradiol 2005;26(1):119-127. (Pubitemid 43079834)
84. Rovaris M, Gass A, Bammer R, et al. Diffusion MRI in multiple sclerosis. Neurology 2005;65(10):1526-1532. (Pubitemid 41689463)
85. Mottershead JP, Schmierer K, Clemence M, et al. High field MRI correlates of myelin content and axonal density in multiple sclerosis - a post-mortem study of the spinal cord. J Neurol 2003;250(11):1293-1301. (Pubitemid 37456888)
86. Poonawalla AH, Hasan KM, Gupta RK, et al. Diffusion-tensor MR imaging of cortical lesions in multiple sclerosis: initial findings. Radiology 2008;246(3):880-886.
87. Rovaris M, Agosta F, Pagani E, Filippi M. Diffusion tensor MR imaging. Neuroimaging Clin N Am 2009;19(1):37-43.
88. Rovaris M, Bozzali M, Iannucci G, et al. Assessment of normal-appearing white and gray matter in patients with primary progressive multiple sclerosis: a diffusion-tensor magnetic resonance imaging study. Arch Neurol 2002;59(9):1406-1412. (Pubitemid 35014804)
89. Oreja-Guevara C, Rovaris M, Iannucci G, et al. Progressive gray matter damage in patients with relapsing-remitting multiple sclerosis: a longitudinal diffusion tensor magnetic resonance imaging study. Arch Neurol 2005;62(4):578-584. (Pubitemid 40489889)
90. Rovaris M, Gallo A, Valsasina P, et al. Short-term accrual of gray matter pathology in patients with progressive multiple sclerosis: an in vivo study using diffusion tensor MRI. Neuroimage 2005;24(4):1139-1146. (Pubitemid 40164515)
91. Rovaris M, Judica E, Gallo A, et al. Grey matter damage predicts the evolution of primary progressive multiple sclerosis at 5 years. Brain 2006;129(Pt 10):2628-2634. (Pubitemid 44522096)
92. Rovaris M, Iannucci G, Falautano M, et al. Cognitive dysfunction in patients with mildly disabling relapsing-remitting multiple sclerosis: an exploratory study with diffusion tensor MR imaging. J Neurol Sci 2002;195(2):103-109. (Pubitemid 34202286)
93. Lin X, Tench CR, Morgan PS, Niepel G, Constantinescu CS. 'Importance sampling' in MS: use of diffusion tensor tractography to quantify pathology related to specific impairment. J Neurol Sci 2005;237(1-2):13-19. (Pubitemid 41384008)
94. Wilson M, Tench CR, Morgan PS, Blumhardt LD. Pyramidal tract mapping by diffusion tensor magnetic resonance imaging in multiple sclerosis: improving correlations with disability. J Neurol Neurosurg Psychiatry 2003;74(2):203-207. (Pubitemid 36160681)
95. Pagani E, Filippi M, Rocca MA, Horsfield MA. A method for obtaining tract-specific diffusion tensor MRI measurements in the presence of disease: application to patients with clinically isolated syndromes suggestive of multiple sclerosis. Neuroimage 2005;26(1):258-265. (Pubitemid 40602905)
96. Ciccarelli O, Toosy AT, Hickman SJ, et al. Optic radiation changes after optic neuritis detected by tractography-based group mapping. Hum Brain Mapp 2005;25(3):308-316. (Pubitemid 40911341)
97. Mesaros S, Rocca MA, Riccitelli G, et al. Corpus callosum damage and cognitive dysfunction in benign MS. Hum Brain Mapp 2009;30(8):2656-2666.
98. Ozturk A, Smith SA, Gordon-Lipkin EM, et al. MRI of the corpus callosum in multiple sclerosis: association with disability. Mult Scler 2010;16(2):166-177.
99. Ceccarelli A, Rocca MA, Pagani E, et al. The topographical distribution of tissue injury in benign MS: a 3T multiparametric MRI study. Neuroimage 2008;39(4):1499-1509.
100. Bodini B, Khaleeli Z, Cercignani M, Miller DH, Thompson AJ, Ciccarelli O. Exploring the relationship between white matter and gray matter damage in early primary progressive multiple sclerosis: an in vivo study with TBSS and VBM. Hum Brain Mapp 2009;30(9):2852-2861.
101. Raz E, Cercignani M, Sbardella E, et al. Clinically isolated syndrome suggestive of multiple sclerosis: voxelwise regional investigation of white and gray matter. Radiology 2010;254(1):227-234.
102. Roosendaal SD, Geurts JJ, Vrenken H, et al. Regional DTI differences in multiple sclerosis patients. Neuroimage 2009;44(4):1397-1403.
103. Dineen RA, Vilisaar J, Hlinka J, et al. Disconnection as a mechanism for cognitive dysfunction in multiple sclerosis. Brain 2009;132(Pt 1):239-249.
104. Giorgio A, Palace J, Johansen-Berg H, et al. Relationships of brain white matter micro-structure with clinical and MR measures in relapsing-remitting multiple sclerosis. J Magn Reson Imaging 2010;31(2):309-316.
105. Sajja BR, Wolinsky JS, Narayana PA. Proton magnetic resonance spectroscopy in multiple sclerosis. Neuroimaging Clin N Am 2009;19(1):45-58.
106. Sharma R, Narayana PA, Wolinsky JS. Grey matter abnormalities in multiple sclerosis: proton magnetic resonance spectroscopic imaging. Mult Scler 2001;7(4):221-226. (Pubitemid 32780691)
107. Chard DT, Griffin CM, McLean MA, et al. Brain metabolite changes in cortical grey and normal-appearing white matter in clinically early relapsing-remitting multiple sclerosis . Brain 2002;125(Pt 10):2342-2352.
108. Sarchielli P, Presciutti O, Tarducci R, et al. Localized (1)H magnetic resonance spectroscopy in mainly cortical gray matter of patients with multiple sclerosis. J Neurol 2002;249(7):902-910.
109. Adalsteinsson E, Langer-Gould A, Homer RJ, et al. Gray matter N-acetyl aspartate deficits in secondary progressive but not relapsing-remitting multiple sclerosis. AJNR Am J Neuroradiol 2003;24(10):1941-1945. (Pubitemid 37444842)
110. Cifelli A, Arridge M, Jezzard P, Esiri MM, Palace J, Matthews PM. Thalamic neuro-degeneration in multiple sclerosis. Ann Neurol 2002;52(5):650-653.
111. Inglese M, Liu S, Babb JS, Mannon LJ, Grossman RI, Gonen O. Three-dimensional proton spectroscopy of deep gray matter nuclei in relapsing-remitting MS. Neurology 2004;63(1):170-172. (Pubitemid 38943801)
112. Geurts JJ, Reuling IE, Vrenken H, et al. MR spectroscopic evidence for thalamic and hippocampal, but not cortical, damage in multiple sclerosis. Magn Reson Med 2006;55(3):478-483. (Pubitemid 43352544)
113. Filippi M, Bozzali M, Rovaris M, et al. Evidence for widespread axonal damage at the earliest clinical stage of multiple sclerosis. Brain 2003;126(Pt 2):433-437. (Pubitemid 36172747)
114. Fernando KT, McLean MA, Chard DT, et al. Elevated white matter myo-inositol in clinically isolated syndromes suggestive of multiple sclerosis. Brain 2004;127(Pt 6):1361-1369. (Pubitemid 38745514)
115. Sastre-Garriga J, Ingle GT, Chard DT, et al. Metabolite changes in normal-appearing gray and white matter are linked with disability in early primary progressive multiple sclerosis. Arch Neurol 2005;62(4):569-573. (Pubitemid 40489887)
116. Staffen W, Zauner H, Mair A, et al. Magnetic resonance spectroscopy of memory and frontal brain region in early multiple sclerosis. J Neuropsychiatry Clin Neurosci 2005;17(3):357-363. (Pubitemid 46179299)
117. Gadea M, Martínez-Bisbal MC, Marti-Bonmatí L, et al. Spectroscopic axonal damage of the right locus coeruleus relates to selective attention impairment in early stage relapsing-remitting multiple sclerosis. Brain 2004;127(Pt 1):89-98. (Pubitemid 38055348)
118. Summers M, Swanton J, Fernando K, et al. Cognitive impairment in multiple sclerosis can be predicted by imaging early in the disease. J Neurol Neurosurg Psychiatry 2008;79(8):955-958.
119. Inglese M, Madelin G, Oesingmann N, et al. Brain tissue sodium concentration in multiple sclerosis: a sodium imaging study at 3 tesla. Brain 2010;133(Pt 3):847-857.
120. Craelius W, Migdal MW, Luessenhop CP, Sugar A, Mihalakis I. Iron deposits surrounding multiple sclerosis plaques. Arch Pathol Lab Med 1982;106(8):397-399.
121. Lassmann H, Brück W, Lucchinetti CF. The immunopathology of multiple sclerosis: an overview. Brain Pathol 2007;17(2):210-218. (Pubitemid 46466140)
122. Stankiewicz J, Panter SS, Neema M, Arora A, Batt CE, Bakshi R. Iron in chronic brain disorders: imaging and neurotherapeutic implications. Neurotherapeutics 2007;4(3):371-386. (Pubitemid 46962416)
123. Neema M, Stankiewicz J, Arora A, et al. T1- and T2-based MRI measures of diffuse gray matter and white matter damage in patients with multiple sclerosis. J Neuroimaging 2007;17(Suppl 1):16S-21S.
124. Ceccarelli A, Rocca MA, Neema M, et al. Deep gray matter T2 hypointensity is present in patients with clinically isolated syndromes suggestive of multiple sclerosis. Mult Scler 2010;16(1):39-44.
125. Neema M, Arora A, Healy BC, et al. Deep gray matter involvement on brain MRI scans is associated with clinical progression in multiple sclerosis. J Neuroimaging 2009;19(1):3-8.
126. Khalil M, Enzinger C, Langkammer C, et al. Quantitative assessment of brain iron by R(2)* relaxometry in patients with clinically isolated syndrome and relapsing-remitting multiple sclerosis. Mult Scler 2009;15(9):1048-1054.
127. Ge Y, Jensen JH, Lu H, et al. Quantitative assessment of iron accumulation in the deep gray matter of multiple sclerosis by magnetic field correlation imaging. AJNR Am J Neuroradiol 2007;28(9):1639-1644. (Pubitemid 47598131)
128. Haacke EM, Garbern J, Miao Y, Habib C, Liu M. Iron stores and cerebral veins in MS studied by susceptibility weighted imaging. Int Angiol 2010;29(2):149-157.
129. Zivadinov R, Schirda C, Dwyer MG, et al. Chronic cerebrospinal venous insufficiency and iron deposition on susceptibility-weighted imaging in patients with multiple sclerosis: a pilot case-control study. Int Angiol 2010;29(2):158-175.
130. Zamboni P, Galeotti R, Menegatti E, et al. Chronic cerebrospinal venous insufficiency in patients with multiple sclerosis. J Neurol Neurosurg Psychiatry 2009;80(4):392-399.
131. Ge Y, Zohrabian VM, Osa EO, et al. Diminished visibility of cerebral venous vasculature in multiple sclerosis by susceptibility-weighted imaging at 3.0 Tesla. J Magn Reson Imaging 2009;29(5):1190-1194.
132. Wakefield AJ, More LJ, Difford J, McLaughlin JE. Immunohistochemical study of vascular injury in acute multiple sclerosis. J Clin Pathol 1994;47(2):129-133. (Pubitemid 24095465)
133. Inglese M, Park SJ, Johnson G, et al. Deep gray matter perfusion in multiple sclerosis: dynamic susceptibility contrast perfusion magnetic resonance imaging at 3 T. Arch Neurol 2007;64(2):196-202.
134. Varga AW, Johnson G, Babb JS, Herbert J, Grossman RI, Inglese M. White matter hemodynamic abnormalities precede subcortical gray matter changes in multiple sclerosis. J Neurol Sci 2009;282(1-2):28-33.
135. Adhya S, Johnson G, Herbert J, et al. Pattern of hemodynamic impairment in multiple sclerosis: dynamic susceptibility contrast perfusion MR imaging at 3.0 T. Neuroimage 2006;33(4):1029-1035. (Pubitemid 44708796)
136. Inglese M, Adhya S, Johnson G, et al. Perfusion magnetic resonance imaging correlates of neuropsychological impairment in multiple sclerosis. J Cereb Blood Flow Metab 2008;28(1):164-171.
137. Saindane AM, Law M, Ge Y, Johnson G, Babb JS, Grossman RI. Correlation of diffusion tensor and dynamic perfusion MR imaging metrics in normal-appearing corpus callosum: support for primary hypoperfusion in multiple sclerosis. AJNR Am J Neuroradiol 2007;28(4):767-772. (Pubitemid 46608622)
138. Filippi M, Rocca MA. Functional MR imaging in multiple sclerosis. Neuroimaging Clin N Am 2009;19(1):59-70.
139. Rocca MA, Colombo B, Falini A, et al. Cortical adaptation in patients with MS: a cross-sectional functional MRI study of disease phenotypes. Lancet Neurol 2005;4(10):618-626. (Pubitemid 41317296)
140. Rocca MA, Absinta M, Ghezzi A, Moiola L, Comi G, Filippi M. Is a preserved functional reserve a mechanism limiting clinical impairment in pediatric MS patients? Hum Brain Mapp 2009;30(9):2844-2851.
141. Rocca MA, Ceccarelli A, Rodegher M, et al. Preserved brain adaptive properties in patients with benign multiple sclerosis. Neurology 2010;74(2):142-149.
142. Filippi M, Rocca MA, Falini A, et al. Correlations between structural CNS damage and functional MRI changes in primary progressive MS. Neuroimage 2002;15(3):537-546. (Pubitemid 34852521)
143. Rocca MA, Matthews PM, Caputo D, et al. Evidence for widespread movement-associated functional MRI changes in patients with PPMS. Neurology 2002;58(6):866-872. (Pubitemid 34242060)
144. Penner IK, Rausch M, Kappos L, Opwis K, Radü EW. Analysis of impairment related functional architecture in MS patients during performance of different attention tasks. J Neurol 2003;250(4):461-472. (Pubitemid 36459754)
145. Rocca MA, Agosta F, Colombo B, et al. fMRI changes in relapsing-remitting multiple sclerosis patients complaining of fatigue after IFNbeta-1a injection. Hum Brain Mapp 2007;28(5):373-382. (Pubitemid 46717362)
146. Rocca MA, Pagani E, Absinta M, et al. Altered functional and structural connectivities in patients with MS: a 3-T study. Neurology 2007;69(23):2136- 2145. (Pubitemid 350294694)
147. Rocca MA, Valsasina P, Ceccarelli A, et al. Structural and functional MRI correlates of Stroop control in benign MS. Hum Brain Mapp 2009;30(1):276-290.
148. Roosendaal SD, Schoonheim MM, Hulst HE, et al. Resting state networks change in clinically isolated syndrome. Brain 2010;133(Pt 6):1612-1621.
149. Rocca MA, Valsasina P, Absinta M, et al. Default-mode network dysfunction and cognitive impairment in progressive MS. Neurology 2010;74(16):1252-1259.
150. Lycklama G, Thompson A, Filippi M, et al. Spinal-cord MRI in multiple sclerosis. Lancet Neurol 2003;2(9):555-562. (Pubitemid 36994995)
151. Poonawalla AH, Hou P, Nelson FA, Wolinsky JS, Narayana PA. Cervical spinal cord lesions in multiple sclerosis: T1-weighted inversion-recovery MR imaging with phase-sensitive reconstruction. Radiology 2008;246(1):258-264. (Pubitemid 350305051)
152. Brex PA, Leary SM, O'Riordan JI, et al. Measurement of spinal cord area in clinically isolated syndromes suggestive of multiple sclerosis. J Neurol Neurosurg Psychiatry 2001;70(4):544-547. (Pubitemid 32269699)
153. Losseff NA, Kingsley DP, McDonald WI, Miller DH, Thompson AJ. Clinical and magnetic resonance imaging predictors of disability in primary and secondary progressive multiple sclerosis. Mult Scler 1996;1(4):218-222. (Pubitemid 126701671)
154. Agosta F, Filippi M. MRI of spinal cord in multiple sclerosis. J Neuroimaging 2007;17(Suppl 1):46S-49S.
155. Agosta F, Absinta M, Sormani MP, et al. In vivo assessment of cervical cord damage in MS patients: a longitudinal diffusion tensor MRI study. Brain 2007;130(Pt 8):2211-2219.
156. Zackowski KM, Smith SA, Reich DS, et al. Sensorimotor dysfunction in multiple sclerosis and column-specific magnetization transfer-imaging abnormalities in the spinal cord. Brain 2009;132(Pt 5):1200-1209.
157. Ciccarelli O, Wheeler-Kingshott CA, McLean MA, et al. Spinal cord spectroscopy and diffusion-based tractography to assess acute disability in multiple sclerosis. Brain 2007;130(Pt 8):2220-2231. (Pubitemid 47236629)
158. Agosta F, Valsasina P, Absinta M, Sala S, Caputo D, Filippi M. Primary progressive multiple sclerosis: tactile-associated functional MR activity in the cervical spinal cord. Radiology 2009;253(1):209-215.
159. Valsasina P, Agosta F, Absinta M, Sala S, Caputo D, Filippi M. Cervical cord functional MRI changes in relapse-onset MS patients. J Neurol Neurosurg Psychiatry 2010;81(4):405-408.
160. Glisson CC, Galetta SL. Nonconventional optic nerve imaging in multiple sclerosis. Neuroimaging Clin N Am 2009;19(1):71-79.
161. Hickman SJ, Brex PA, Brierley CM, et al. Detection of optic nerve atrophy following a single episode of unilateral optic neuritis by MRI using a fat-saturated short-echo fast FLAIR sequence. Neuroradiology 2001;43(2):123-128. (Pubitemid 32156701)
162. Hickman SJ, Toosy AT, Jones SJ, et al. Serial magnetization transfer imaging in acute optic neuritis. Brain 2004;127(Pt 3):692-700. (Pubitemid 38295482)
163. Hickman SJ, Wheeler-Kingshott CA, Jones SJ, et al. Optic nerve diffusion measurement from diffusion-weighted imaging in optic neuritis. AJNR Am J Neuroradiol 2005;26(4):951-956. (Pubitemid 43079798)
164. Trip SA, Schlottmann PG, Jones SJ, et al. Optic nerve atrophy and retinal nerve fibre layer thinning following optic neuritis: evidence that axonal loss is a substrate of MRI-detected atrophy. Neuroimage 2006;31(1):286-293. (Pubitemid 43728985)
165. Kolbe S, Chapman C, Nguyen T, et al. Optic nerve diffusion changes and atrophy jointly predict visual dysfunction after optic neuritis. Neuroimage 2009;45(3):679-686.
166. Werring DJ, Bullmore ET, Toosy AT, et al. Recovery from optic neuritis is associated with a change in the distribution of cerebral response to visual stimulation: a functional magnetic resonance imaging study. J Neurol Neurosurg Psychiatry 2000;68(4):441-449. (Pubitemid 30248743)
167. Wattjes MP, Harzheim M, Lutterbey GG, et al. Does high field MRI allow an earlier diagnosis of multiple sclerosis? J Neurol 2008;255(8):1159-1163.
168. Wattjes MP, Lutterbey GG, Gieseke J, et al. Double inversion recovery brain imaging at 3T: diagnostic value in the detection of multiple sclerosis lesions. AJNR Am J Neuroradiol 2007;28(1):54-59. (Pubitemid 46147534)
169. Ge Y, Zohrabian VM, Grossman RI. Seven-Tesla magnetic resonance imaging: new vision of microvascular abnormalities in multiple sclerosis. Arch Neurol 2008;65(6):812-816. (Pubitemid 351831461)
170. Hammond KE, Metcalf M, Carvajal L, et al. Quantitative in vivo magnetic resonance imaging of multiple sclerosis at 7 Tesla with sensitivity to iron. Ann Neurol 2008;64(6):707-713.
171. Tallantyre EC, Brookes MJ, Dixon JE, Morgan PS, Evangelou N, Morris PG. Demonstrating the perivascular distribution of MS lesions in vivo with 7-Tesla MRI. Neurology 2008;70(22):2076-2078.
172. Mainero C, Benner T, Radding A, et al. In vivo imaging of cortical pathology in multiple sclerosis using ultra-high field MRI. Neurology 2009;73(12):941-948.
173. Srinivasan R, Ratiney H, Hammond-Rosenbluth KE, Pelletier D, Nelson SJ. MR spectroscopic imaging of glutathione in the white and gray matter at 7 T with an application to multiple sclerosis. Magn Reson Imaging 2010;28(2):163-170.
174. Barkhof F, Filippi M, Miller DH, Tofts P, Kappos L, Thompson AJ. Strategies for optimizing MRI techniques aimed at monitoring disease activity in multiple sclerosis treatment trials. J Neurol 1997;244(2):76-84. (Pubitemid 27057951)
175. Filippi M, Horsfield MA, Adèr HJ, et al. Guidelines for using quantitative measures of brain magnetic resonance imaging abnormalities in monitoring the treatment of multiple sclerosis. Ann Neurol 1998;43(4): 499-506. (Pubitemid 28231726)
176. Goodin DS. Magnetic resonance imaging as a surrogate outcome measure of disability in multiple sclerosis: have we been overly harsh in our assessment? Ann Neurol 2006; 59(4):597-605.
177. Sormani MP, Bonzano L, Roccatagliata L, Cutter GR, Mancardi GL, Bruzzi P. Magnetic resonance imaging as a potential surrogate for relapses in multiple sclerosis: a meta-analytic approach. Ann Neurol 2009; 65(3):268-275.
178. Sormani MP, Bonzano L, Roccatagliata L, Mancardi GL, Uccelli A, Bruzzi P. Surrogate endpoints for EDSS worsening in multiple sclerosis. A meta-analytic approach. Neurology 2010;75(4):302-309.
179. Simon JH, Lull J, Jacobs LD, et al. A longitudinal study of T1 hypointense lesions in relapsing MS: MSCRG trial of interferon beta-1a. Multiple Sclerosis Collaborative Research Group. Neurology 2000;55(2): 185-192. (Pubitemid 30604616)
180. Barkhof F, van Waesberghe JH, Filippi M, et al. T(1) hypointense lesions in secondary progressive multiple sclerosis: effect of interferon beta-1b treatment. Brain 2001; 124(Pt 7):1396-1402.
181. Filippi M, Rovaris M, Rice GP, et al. The effect of cladribine on T(1) 'black hole' changes in progressive MS. J Neurol Sci 2000;176(1):42-44.
182. Patti F, Amato MP, Filippi M, Gallo P, Trojano M, Comi GC. A double blind, placebo- controlled, phase II, add-on study of cyclophosphamide (CTX) for 24 months in patients affected by multiple sclerosis on a background therapy with interferon-beta study denomination: CYCLIN. J Neurol Sci 2004;223(1):69-71. (Pubitemid 38903265)
183. Paolillo A, Coles AJ, Molyneux PD, et al. Quantitative MRI in patients with secondary progressive MS treated with monoclonal antibody Campath 1H. Neurology 1999; 53(4):751-757. (Pubitemid 29448295)
184. Rudick RA, Fisher E, Lee JC, Simon J, Jacobs L. Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS. Multiple Sclerosis Collaborative Research Group. Neurology 1999;53(8):1698-1704. (Pubitemid 29530342)
185. Simon JH. From enhancing lesions to brain atrophy in relapsing MS. J Neuroimmunol 1999;98(1):7-15. (Pubitemid 29295401)
186. Filippi M, Rovaris M, Iannucci G, Mennea S, Sormani MP, Comi G. Whole brain volume changes in patients with progressive MS treated with cladribine. Neurology 2000;55(11):1714-1718.
187. Molyneux PD, Kappos L, Polman C, et al. The effect of interferon beta-1b treatment on MRI measures of cerebral atrophy in secondary progressive multiple sclerosis. European Study Group on Interferon beta-1b in secondary progressive multiple sclerosis. Brain 2000;123(Pt 11):2256-2263.
188. Rovaris M, Comi G, Rocca MA, Wolinsky JS, Filippi M;European/Canadian Glatiramer Acetate Study Group. Short-term brain volume change in relapsing-remitting multiple sclerosis: effect of glatiramer acetate and implications. Brain 2001;124(Pt 9):1803-1812.
189. Miller DH, Soon D, Fernando KT, et al. MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS. Neurology 2007;68(17):1390-1401. (Pubitemid 46659091)
190. Sormani MP, Rovaris M, Valsasina P, Wolinsky JS, Comi G, Filippi M. Measurement error of two different techniques for brain atrophy assessment in multiple sclerosis. Neurology 2004;62(8):1432-1434. (Pubitemid 38526067)
191. Rudick RA, Lee JC, Simon J, Ransohoff RM, Fisher E. Defining interferon beta response status in multiple sclerosis patients. Ann Neurol 2004;56(4):548-555. (Pubitemid 39319345)
192. Río J, Rovira A, Tintoré M, et al. Relationship between MRI lesion activity and response to IFN-beta in relapsing-remitting multiple sclerosis patients. Mult Scler 2008; 14(4):479-484. (Pubitemid 351943860)
193. Río J, Castilló J, Rovira A, et al. Measures in the first year of therapy predict the response to interferon beta in MS. Mult Scler 2009;15(7):848-853.
194. Tomassini V, Paolillo A, Russo P, et al. Predictors of long-term clinical response to interferon beta therapy in relapsing multiple sclerosis. J Neurol 2006;253(3):287-293.
195. Freedman MS, Patry DG, Grand'Maison F, et al. Treatment optimization in multiple sclerosis. Can J Neurol Sci 2004;31(2): 157-168. (Pubitemid 38724807)
196. Rocca MA, Agosta F, Sormani MP, et al. A three-year, multi-parametric MRI study in patients at presentation with CIS. J Neurol 2008;255(5):683-691.
197. Rovaris M, Judica E, Sastre-Garriga J, et al. Large-scale, multicentre, quantitative MRI study of brain and cord damage in primary progressive multiple sclerosis. Mult Scler 2008;14(4):455-464. (Pubitemid 351943857)
198. Narayana PA, Wolinsky JS, Rao SB, He R, Mehta M;PROMiSe Trial MRSI Group. Multicentre proton magnetic resonance spectroscopy imaging of primary progressive multiple sclerosis. Mult Scler 2004; 10(Suppl 1):S73-S78.
199. Sajja BR, Narayana PA, Wolinsky JS, Ahn CW; PROMiSe Trial MRSI Group. Longitudinal magnetic resonance spectroscopic imaging of primary progressive multiple sclerosis patients treated with glatiramer acetate: multicenter study. Mult Scler 2008;14(1): 73-80.
200. Pagani E, Hirsch JG, Pouwels PJ, et al. Intercenter differences in diffusion tensor MRI acquisition. J Magn Reson Imaging 2010; 31(6):1458-1468.
201. Wegner C, Filippi M, Korteweg T, et al. Relating functional changes during hand movement to clinical parameters in patients with multiple sclerosis in a multicentre fMRI study. Eur J Neurol 2008; 15(2):113-122.
202. Rocca MA, Absinta M, Valsasina P, et al. Abnormal connectivity of the sensorimotor network in patients with MS: a multicenter fMRI study. Hum Brain Mapp 2009;30(8): 2412-2425.
203. Barkhof F, Calabresi PA, Miller DH, Reingold SC. Imaging outcomes for neuroprotection and repair in multiple sclerosis trials. Nat Rev Neurol 2009;5(5):256-266.